anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Minocycline
Trial phase: Phase 2
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Eligibility criteria:
Inclusion Criteria:

Ability to complete questionnaires by themselves or with assistance
Planned paclitaxel at a dose of 80 mg/m2 IV given, in the adjuvant breast cancer (postoperative or neo-adjuvant) setting, every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy (trastuzumab and/or other antibody and/or small molecule treatment is allowed, except for PARP inhibitors)
Life expectancy > 6 months
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Negative pregnancy test (serum or urine) done =< 7 days prior to registration, for women of childbearing potential only (determined per clinician discretion)

Exclusion Criteria:

Any of the following:

Pregnant women
Nursing women
Men or women of childbearing potential who are unwilling to employ adequate contraception
Previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause
History of allergic or other adverse reactions to minocycline
Prior exposure to neurotoxic chemotherapy
Diagnosis of fibromyalgia
Current or planned use of methoxyflurane, oral contraceptives, isotretinoin, penicillin, or ergot alkaloids
History of allergic or other adverse reactions to tetracycline
Intervention: Acthargel
Trial phase: Phase 4
SMILES: CSCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(N)CO)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CC(N)=O)C(=O)NCC(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C)C(C)C)C(C)C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: H.P. Acthar Gel: 80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
Eligibility criteria:
Inclusion Criteria:

A highly probable diagnosis of sarcoidosis, as determined using the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Sarcoidosis Organ Assessment Instrument (Judson et al., 2014), with involvement not limited to the central nervous system.
At the time of enrollment, a history of clinical deterioration based on the development of new symptoms or worsening previously present symptoms with confirmation by clinical examination and objective clinical testing.
If on steroids, on a stable dose of the medication for at least 3 months.

Exclusion Criteria:
Intervention: Baclofen
Trial phase: Phase 2
ATC code: M03BX01
SMILES: NCC(CC(=O)O)c1ccc(Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
Eligibility criteria:
Inclusion Criteria:

Cirrhosis
Presence of muscle cramps on a regular basis

Exclusion Criteria:

Allergy or hypersensitivity to Baclofen
Active or untreated Portosystemic encephalopathy
Active alcohol or substance abuse
Age less than 18
Pregnancy
Concomitant use of narcotic pain medication, other muscle relaxer, or other anti-spastic agent
Concomitant use of Tricyclic Antidepressant due to drug interaction
History of chronic kidney disease defined by GFR < 30 (using MDRD equation)
Subject is institutionalized or a prisoner
Inability or unwillingness to give informed consent
Expected lifespan less than 3 months
Severe or poorly controlled coexisting medical conditions or other significant issues as determined by the principal investigator to hinder the ability to adhere to study protocols
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: bupivacaine liposome suspension periarticular injection

bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection
Eligibility criteria:
Inclusion Criteria:

TKA candidacy
Osteoarthritis
Failure of non-operative treatments to control knee pain
Patients able to understand and agree to study inclusion

Exclusion Criteria:

Subjects have orthopaedic and medical co-morbidities that would thwart postoperative pain control such as extra-articular pathology with referred pain to the knee (spinal stenosis, neuropathy,ipsilateral hip disease)
Severe knee deformity
Post-traumatic and inflammatory arthritis
BMI above 40
Patients unable to receive multimodal pain remitting agents
Active knee sepsis
Remote sites of active infection
Diabetes with A1C > 7
ASA class > lll
Cardiac disease failing medical clearance
Severe liver disease
PAD with AAI < 0.75
Seizure disorder
Allergic to any pain remitting agent
Alcohol abuse
Smoking abuse
Intervention: Labetalol
Trial phase: Phase 4
ATC code: C07AG01 | C07BG01 | C07CG01
SMILES: CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1208
Group description: Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used

Anti-hypertensive therapy: 1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
Eligibility criteria:
Inclusion Criteria:

Women with chronic hypertension in pregnancy with new or untreated chronic hypertension, blood pressure 140-159 systolic or 90-104 diastolic OR known chronic hypertension on monotherapy and taking any antihypertensive and blood pressure ≤159/104 (including those with blood pressure <140/90);
Singleton; and
viable pregnancy <23 weeks of gestation.

Exclusion Criteria:

Blood pressures prior to randomization ≥160 systolic or ≥105 diastolic (with or without treatment);
Severe hypertension including patients currently treated with >1 antihypertensive medication (more likely to have severe chronic hypertension);
Multi-fetal pregnancy;
Known secondary cause of chronic hypertension;

High-risk co-morbidities for which treatment may be indicated:

Diabetes mellitus diagnosed at age ≤10 years or duration of diagnosis ≥20 years
Diabetes mellitus complicated by end organ damage (retinopathy, nephropathy, heart disease, transplant)

Chronic kidney disease - including baseline proteinuria (>300mg/24-hr, protein/creatinine ratio ≥0.3, or persistent 1+ proteinuria*) or creatinine >1.2.

*If a dipstick value at screening is more than trace, a clean catch or catheter urine should be obtained and re-tested by dipstick. If this shows trace or absence of protein, the patient is included. If it again shows 1+ protein, the patient is excluded until a 24-hr urine <300mg/24hr or p/c ratio is <0.3. If a p/c ratio is >0.3, the patient may be included if a 24-hour urine is < 300 mg.

Cardiac disorders: cardiomyopathy, angina, CAD
Prior stroke
Retinopathy
Sickle cell disease
Known major fetal anomaly;
Known fetal demise;
Suspected IUGR;
Membrane rupture or planned termination prior to randomization;
Plan to deliver outside the consortium centers (unless approved by the Clinical Coordinating Center) or unlikely to follow-up in the opinion of study staff or previous participation in this trial;
Contraindication to labetalol and nifedipine (e.g. know hypersensitivity);
Current substance abuse or addiction (cocaine, methamphetamine)
Participation in another trial without prior approval (CHAP participants will not be enrolled in other trials without prior approval by protocol committee)
Physician or provider refusal
Patient refusal *The minimum age varies by center
Intervention: Cobimetinib
Trial phase: Phase 1
ATC code: L01EE02 | L01XE38
SMILES: O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) received single oral dose of 10 mg cobimetinib (two 5 mg capsules) on Day 1 of study.
Eligibility criteria:
Inclusion Criteria:

Male and female subjects between 18 and 74 years of age, inclusive
Body weight >/=45 kg and body mass index between 17 and 41 kg/m2, inclusive
Subjects with hepatic impairment must have a Child-Pugh score of 5 to 6 (mild), 7 to 9 (moderate), or 10 to 15 (severe) and have stable hepatic insufficiency within 1 month prior to Screening and a stable medication regimen for at least 1 month prior to Check-in
Agreement to use highly effective contraceptive methods as defined in the protocol

Exclusion Criteria:

Significant illness, including infections, or hospitalization within the 2 weeks prior to dosing, except for subjects with hepatic impairment who due to their liver disease may be affected by significant medical problems which require frequent hospitalizations. Invasive systemic fungal infections need to be fully treated prior to study entry
Significant history or clinical manifestations of any cardiac event that would put the subject at risk in the opinion of the Investigator
Use of drugs of abuse within 1 month of Screening or during the entire study
Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study
Intervention: Cobimetinib
Trial phase: Phase 1
ATC code: L01EE02 | L01XE38
SMILES: O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Participants with severe hepatic impairment (Child-Pugh Class A, score of 10 to 15, inclusive) received single oral dose of 10 mg cobimetinib (two 5 mg capsules) on Day 1 of study.
Eligibility criteria:
Inclusion Criteria:

Male and female subjects between 18 and 74 years of age, inclusive
Body weight >/=45 kg and body mass index between 17 and 41 kg/m2, inclusive
Subjects with hepatic impairment must have a Child-Pugh score of 5 to 6 (mild), 7 to 9 (moderate), or 10 to 15 (severe) and have stable hepatic insufficiency within 1 month prior to Screening and a stable medication regimen for at least 1 month prior to Check-in
Agreement to use highly effective contraceptive methods as defined in the protocol

Exclusion Criteria:

Significant illness, including infections, or hospitalization within the 2 weeks prior to dosing, except for subjects with hepatic impairment who due to their liver disease may be affected by significant medical problems which require frequent hospitalizations. Invasive systemic fungal infections need to be fully treated prior to study entry
Significant history or clinical manifestations of any cardiac event that would put the subject at risk in the opinion of the Investigator
Use of drugs of abuse within 1 month of Screening or during the entire study
Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study
Intervention: Ciprofloxacin
Trial phase: Phase 3
ATC code: J01MA02 | J01RA10 | J01RA11 | J01RA12 | S01AE03 | S02AA15 | S03AA07
SMILES: O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 72
Group description: 500 mg, twice daily for 1 week (oral).

Ciprofloxacin: 500 mg, twice daily for 1 week (oral)
Eligibility criteria:
Inclusion Criteria:

Diagnosis of COPD confirmed spirometrically at screening
COPD exacerbation with treatment commenced 14 days prior to study enrolment and treated with 5-14 days of a non-quinolone antibiotic.
Exacerbation here will be defined as an episode of symptomatic worsening of COPD that was treated by the patient's attending clinician. Confirmation of the initial exacerbation diagnosis will be provided from the case notes, referral letter, or directly from the treating clinician, and will be documented in the CRF.
Age: ≥ 45 years of age at screening.
Persistent symptoms and/or a CRP≥8mg/L when assessed 2 weeks after exacerbation onset
Able to complete questionnaires for health status and symptoms and keep written diary cards
Severity of disease: Patients with a measured FEV1<80% of predicted normal values at 2 weeks post exacerbation
Able and willing to give signed and dated written informed consent to participate.

Exclusion Criteria:

Other clinically predominant chronic respiratory disease.
Intubated and receiving mechanical ventilation
Patients with known hypersensitivity to the antibiotic under evaluation, to other quinolones or any excipients of the IMP/placebo.
Patients with a prior history of tendonopathy or tendon rupture
Elderly patients taking long term systemic corticosteroids
Patients on long term antibiotics for other conditions
Patient too unwell for randomisation, i.e. requiring retreatment in the judgment of the study doctor
Female patients who are pregnant or planning on becoming pregnant during the study, or are breastfeeding.
Patient taking clinically significant contraindicated medication as per the SmPC s, such as use of concomitant tizanidine or methotrexate.
Intervention: Simvastatin
Trial phase: Phase 1
ATC code: A10BH51 | C10AA01 | C10BA02 | C10BA04 | C10BX01 | C10BX04
SMILES: CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 16
Group description: Single oral dose of 20 mg simvastatin on Day 1.
Eligibility criteria:
Inclusion Criteria:

Healthy participants as determined by medical history, physical examination, clinical laboratory tests, and electrocardiograms (ECGs).
Have a body mass index (BMI) between 18 and 32.0 kilograms per square meter (kg/m^2) inclusive, at screening
Female participants must be of non-childbearing potential

Exclusion Criteria:

In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study
Intervention: Cyclosporine
Trial phase: Phase 1 | Phase 2
ATC code: L04AD01 | S01XA18
SMILES: CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Standard mouth wash preparation administered by ingested mouth rinse three times per day.

The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.

Mouthwash-standard pharmacy preparation: Standard mouth wash preparation administered by ingested mouth rinse three times per day.

The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.
Eligibility criteria:
Inclusion Criteria:

≥ grade 2 oral mucositis related to chemotherapy for cancer
Ability to understand and the willingness to review and sign a written informed consent document.
≥ 18 years of age
Willingness to use adequate contraception prior to study entry, for the duration of study participation and for 30 days after the last dose for women of child-bearing potential and men

Exclusion Criteria:

Current use of therapeutic doses of anticoagulants such as warfarin or antiplatelet agents (prophylactic doses and agents are acceptable)
Biliary tract obstruction or cholelithiasis
History of gastric or duodenal ulcers or hyperacidity syndromes
AST or ALT > 2 x ULN
Total bilirubin ≥ 2 x ULN
INR > 1.5
Previous stem cell transplant (allogeneic or autologous)
Preexisting oral disease, such as active oral infection, trauma to the oral mucosa or oral - ulceration prior to chemotherapy
Known allergy/hypersensitivity to curcumin, yellow food coloring, or other members of the - Zingiberaceae (ginger) family
Pregnant or breastfeeding
Intervention: Curcumin
Trial phase: Phase 1 | Phase 2
SMILES: COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).

Curcumin: After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
Eligibility criteria:
Inclusion Criteria:

≥ grade 2 oral mucositis related to chemotherapy for cancer
Ability to understand and the willingness to review and sign a written informed consent document.
≥ 18 years of age
Willingness to use adequate contraception prior to study entry, for the duration of study participation and for 30 days after the last dose for women of child-bearing potential and men

Exclusion Criteria:

Current use of therapeutic doses of anticoagulants such as warfarin or antiplatelet agents (prophylactic doses and agents are acceptable)
Biliary tract obstruction or cholelithiasis
History of gastric or duodenal ulcers or hyperacidity syndromes
AST or ALT > 2 x ULN
Total bilirubin ≥ 2 x ULN
INR > 1.5
Previous stem cell transplant (allogeneic or autologous)
Preexisting oral disease, such as active oral infection, trauma to the oral mucosa or oral - ulceration prior to chemotherapy
Known allergy/hypersensitivity to curcumin, yellow food coloring, or other members of the - Zingiberaceae (ginger) family
Pregnant or breastfeeding
Intervention: Qsymia
Trial phase: Phase 2
ATC code: A08AA51
SMILES: CC(C)(N)Cc1ccccc1.CC1(C)OC2COC3(COS(N)(=O)=O)OC(C)(C)OC3C2O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: All subjects enrolled in the study will be placed on the study medication.

Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
Eligibility criteria:
Inclusion Criteria:

BMI ≥ 50 kg/m2
Determined to be a good candidate for surgery based on medical and psychological exam.
Willing to participate in a 3-6 month medically supervised weight loss plan prior to surgery.
Planning to remain in the reasonable vicinity of the Wake Forest Baptist Health - Weight Management Center for the duration of the study.

Exclusion Criteria:

History of prior weight loss surgery (removal/conversion from band to sleeve will not be excluded)
Pregnant (women of childbearing potential will complete a pregnancy test (blood draw) to make sure they are not pregnant at the time that they initiate the medication). Ongoing monitoring of pregnancy status is the responsibility of the patient and they are instructed as such in the consent form.
Ongoing use of weight loss medication
Contraindications to use of Qsymia, including pregnancy, history of glaucoma, unstable cardiac disease (unstable angina, recent heart attack or stroke (in the past 6 months), uncontrolled arrhythmia), hyperthyroidism, taking monoamine oxidase inhibitors (MAOIs) or allergy to either topiramate or sympathomimetic amines like phentermine.
Intervention: Ledipasvir
Trial phase: Phase 2
ATC code: J05AP51
SMILES: COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Treatment-naive or treatment-experienced participants without cirrhosis received LDV/SOF 90/400 mg FDC tablet once daily for 12 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Chronic genotype 1 or 4 infected patients with sickle cell disease
HCV RNA ≥ 1,000 IU/mL at screening
Cirrhosis determination by transient elastography
Screening laboratory values within defined thresholds
Use of two effective contraception methods if female of childbearing potential or sexually active male

Key Exclusion Criteria:

Pregnant or nursing female
Co-infection with HIV or hepatitis B virus (HBV)
Current or prior history of clinical hepatic decompensation
Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)
History of clinically significant illness or any other medical disorder that may interfere with treatment, assessment or compliance with the protocol

Note: Other protocol defined inclusion/Exclusion criteria may apply.
Intervention: Ledipasvir
Trial phase: Phase 2
ATC code: J05AP51
SMILES: COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Treatment-experienced participants with cirrhosis received LDV/SOF 90/400 mg FDC tablet once daily for 24 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Chronic genotype 1 or 4 infected patients with sickle cell disease
HCV RNA ≥ 1,000 IU/mL at screening
Cirrhosis determination by transient elastography
Screening laboratory values within defined thresholds
Use of two effective contraception methods if female of childbearing potential or sexually active male

Key Exclusion Criteria:

Pregnant or nursing female
Co-infection with HIV or hepatitis B virus (HBV)
Current or prior history of clinical hepatic decompensation
Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)
History of clinically significant illness or any other medical disorder that may interfere with treatment, assessment or compliance with the protocol

Note: Other protocol defined inclusion/Exclusion criteria may apply.
Intervention: SODIUM BICARBONATE
Trial phase: Phase 2
ATC code: B05CB04 | B05XA02
SMILES: O=C([O-])O.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min

Sodium bicarbonate: Administer Sodium bicarbonate 50 mEq IV over 2 minutes
Eligibility criteria:
Inclusion Criteria:

adult cardiac arrest patient with arterial pH <7.1 or bicarbonate <10mmEq/L checked at 10 minutes of cardiopulmonary resuscitation

Exclusion Criteria:

age <18 trauma patient Do Not Resuscitate state
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Normal saline 50cc intravenous injection over 2 min

Normal saline: Placebo
Eligibility criteria:
Inclusion Criteria:

adult cardiac arrest patient with arterial pH <7.1 or bicarbonate <10mmEq/L checked at 10 minutes of cardiopulmonary resuscitation

Exclusion Criteria:

age <18 trauma patient Do Not Resuscitate state